Long non‑coding RNAs in multiple myeloma (Review)

Yang,Chenbo; Liang,Yinghao; Shu,Jiao; Wang,Shuaiyuan; Hong,Yichen; Chen,Kuisheng; Sun,Miaomiao

doi:10.3892/ijo.2023.5517

Long non‑coding RNAs in multiple myeloma (Review)

Authors:
- Chenbo Yang
- Yinghao Liang
- Jiao Shu
- Shuaiyuan Wang
- Yichen Hong
- Kuisheng Chen
- Miaomiao Sun
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Henan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: May 4, 2023 https://doi.org/10.3892/ijo.2023.5517
Article Number: 69
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple myeloma (MM) is one of the three major malignancies of the hematological system in middle‑aged and older individuals. The incidence of MM increases with age and due to its drug resistance and high recurrence, MM seriously harms human health. Long non‑coding RNAs (lncRNAs) are RNA molecules with a length of >200 nt and rarely encode proteins. Numerous studies reported that lncRNAs regulate carcinogenesis and cancer progression. MM‑associated lncRNAs affect features of tumor cells, including proliferation, apoptosis, adhesion and treatment resistance. The present review aims to summarize the latest findings on the roles of lncRNAs in MM to deepen the understanding of this field and provide insight for developing specific diagnostic tools and effective treatment strategies for MM, including novel biomarkers and targeted lncRNA therapeutics.

View Figures

View References

1	Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, et al: Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncol. 4:1221–1227. 2018.
2	Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, et al: Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study. Leukemia. 31:2443–2448. 2017.
3	van de Donk N, Pawlyn C and Yong KL: Multiple myeloma. Lancet. 397:410–427. 2021.
4	Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE, et al: Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 447:799–816. 2007.
5	Yan H and Bu P: Non-coding RNA in cancer. Essays. Biochem. 65:625–639. 2021.
6	Winkle M, Kluiver JL, Diepstra A and van den Berg A: Emerging roles for long noncoding RNAs in B-cell development and malignancy. Crit Rev Oncol Hematol. 120:77–85. 2017.
7	Li Y, Li G, Guo X, Yao H, Wang G and Li C: Non-coding RNA in bladder cancer. Cancer Lett. 485:38–44. 2020.
8	Statello L, Guo CJ, Chen LL and Huarte M: Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 22:96–118. 2021.
9	Zhu J, Fu H, Wu Y and Zheng X: Function of lncRNAs and approaches to lncRNA-protein interactions. Sci China Life Sci. 56:876–885. 2013.
10	Kopp F and Mendell JT: Functional classification and experimental dissection of long noncoding RNAs. Cell. 172:393–407. 2018.
11	Sun Q, Hao Q and Prasanth KV: Nuclear long noncoding RNAs: Key regulators of gene expression. Trends Genet. 34:142–157. 2018.
12	Peng WX, Koirala P and Mo YY: LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 36:5661–5667. 2017.
13	Kazandjian D: Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 43:676–681. 2016.
14	Goyal B, Yadav SRM, Awasthee N, Gupta S, Kunnumakkara AB and Gupta SC: Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer. Biochim Biophys Acta Rev Cancer. 1875:1885022021.
15	Sun Y, Jiang T, Jia Y, Zou J, Wang X and Gu W: LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway. Cell Cycle. 18:2509–2523. 2019.
16	Liu H, Chi Z, Jin H and Yang W: MicroRNA miR-188-5p as a mediator of long non-coding RNA MALAT1 regulates cell proliferation and apoptosis in multiple myeloma. Bioengineered. 12:1611–1626. 2021.
17	Ghafouri-Fard S, Esmaeili M and Taheri M: H19 lncRNA: Roles in tumorigenesis. Biomed Pharmacother. 123:1097742020.
18	Zheng JF, Guo NH, Zi FM and Cheng J: Long noncoding RNA H19 promotes tumorigenesis of multiple myeloma by activating BRD4 signaling by targeting MicroRNA 152-3p. Mol Cell Biol. 40:e00382–19. 2020.
19	Xiong T, Li J, Chen F and Zhang F: PCAT-1: A novel oncogenic long non-coding RNA in human cancers. Int J Biol Sci. 15:847–856. 2019.
20	Shen X, Kong S, Yang Q, Yin Q, Cong H, Wang X and Ju S: PCAT-1 promotes cell growth by sponging miR-129 via MAP3K7/NF-κB pathway in multiple myeloma. J Cell Mol Med. 24:3492–3503. 2020.
21	Onagoruwa OT, Pal G, Ochu C and Ogunwobi OO: Oncogenic role of PVT1 and therapeutic implications. Front Oncol. 10:172020.
22	Yang M, Zhang L, Wang X, Zhou Y and Wu S: Down-regulation of miR-203a by lncRNA PVT1 in multiple myeloma promotes cell proliferation. Arch Med Sci. 14:1333–1339. 2018.
23	Wang M, Zhao HY, Zhang JL, Wan DM, Li YM and Jiang ZX: Dysregulation of LncRNA ANRIL mediated by miR-411-3p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1α. Exp Cell Res. 396:1122802020.
24	Meng YB, He X, Huang YF, Wu QN, Zhou YC and Hao DJ: Long noncoding RNA CRNDE promotes multiple myeloma cell growth by suppressing miR-451. Oncol Res. 25:1207–1214. 2017.
25	Liu Q, Ran R, Song M, Li X, Wu Z, Dai G and Xia R: LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β-catenin/cyclin D1 signaling via PLAGL2. Cell Biol Toxicol. 38:979–993. 2022.
26	Liu H, Shen Y, Xu Y, Wang L, Zhang C, Jiang Y, Hong L, Huang H and Liu H: lncRNA transcription factor 7 is related to deteriorating clinical features and poor prognosis in multiple myeloma, and its knockdown suppresses disease progression by regulating the miR-203-mediated Jagged1-Notch1 signaling pathway. Oncol Lett. 21:4122021.
27	Ding T, Deng R and Huang T: Long non-coding RNA T cell factor 7 is associated with increased disease risk and poor prognosis, and promotes cell proliferation, attenuates cell apoptosis and miR-200c expression in multiple myeloma. Oncol Lett. 21:1292021.
28	Xiao X, Gu Y, Wang G and Chen S: c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma. Int J Biol Macromol. 122:526–537. 2019.
29	Liu Z, Han M, Meng N, Luo J and Fu R: lncRNA MSTRG.29039.1 promotes proliferation by sponging hsa-miR-12119 via JAK2/STAT3 pathway in multiple myeloma. Oxid Med Cell Longev. 2021:99694492021.
30	Wang F, Luo Y, Zhang L, Younis M and Yuan L: The LncRNA RP11-301G19.1/miR-582-5p/HMGB2 axis modulates the proliferation and apoptosis of multiple myeloma cancer cells via the PI3K/AKT signalling pathway. Cancer Gene Ther. 29:292–303. 2022.
31	Chen X, Liu Y, Yang Z, Zhang J, Chen S and Cheng J: LINC01234 promotes multiple myeloma progression by regulating miR-124-3p/GRB2 axis. Am J Transl Res. 11:6600–6618. 2019.
32	Deng M, Yuan H, Liu S, Hu Z and Xiao H: Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA/BCL-2 expression. Cytotherapy. 21:96–106. 2019.
33	Chu M, Fan Y, Wu L, Ma X, Sao J, Yao Y, Zhuang W and Zhang C: Knockdown of lncRNA BDNF-AS inhibited the progression of multiple myeloma by targeting the miR-125a/b-5p-BCL2axis. Immun Ageing. 19:32022.
34	Yang Y and Chen L: Downregulation of lncRNA UCA1 facilitates apoptosis and reduces proliferation in multiple myeloma via regulation of the miR-1271-5p/HGF axis. J Chin Med Assoc. 82:699–709. 2019.
35	Li QY, Chen L, Hu N and Zhao H: Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610/Akt3 axis. Biomed Pharmacother. 103:1727–1732. 2018.
36	Chen L, Hu N, Wang C, Zhao H and Gu Y: Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression. Cell Cycle. 17:319–329. 2018.
37	Fu Y, Liu X, Zhang F, Jiang S, Liu J and Luo Y: Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b. Cell Death Dis. 10:3192019.
38	Sun Y, Pan J, Zhang N, Wei W, Yu S and Ai L: Knockdown of long non-coding RNA H19 inhibits multiple myeloma cell growth via NF-κB pathway. Sci Rep. 7:180792017.
39	Shen X, Shen P, Yang Q, Yin Q, Wang F, Cong H, Wang X and Ju S: Knockdown of long non-coding RNA PCAT-1 inhibits myeloma cell growth and drug resistance via p38 and JNK MAPK pathways. J Cancer. 10:6502–6510. 2019.
40	Handa H, Honma K, Oda T, Kobayashi N, Kuroda Y, Kimura-Masuda K, Watanabe S, Ishihara R, Murakami Y, Masuda Y, et al: Long Noncoding RNA PVT1 is regulated by bromodomain protein BRD4 in multiple myeloma and is associated with disease progression. Int J Mol Sci. 21:71212020.
41	Ronchetti D, Todoerti K, Vinci C, Favasuli V, Agnelli L, Manzoni M, Pelizzoni F, Chiaramonte R, Platonova N, Giuliani N, et al: Expression pattern and biological significance of the lncRNA ST3GAL6-AS1 in multiple myeloma. Cancers (Basel). 12:7822020.
42	Geng W, Guo X, Zhang L, Ma Y, Wang L, Liu Z, Ji H and Xiong Y: Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/β-catenin signaling pathway. Biomed Pharmacother. 107:484–494. 2018.
43	Zhu BZ and Lin L: Effects of lncRNA HOTAIR on proliferation and apoptosis of myeloma cells through NF-κB pathway. Eur Rev Med Pharmacol Sci. 23:10042–10048. 2019.
44	Liu Z, Gao H, Peng Q and Yang Y: Long noncoding RNA LUCAT1 promotes multiple myeloma cell growth by regulating the TGF-β signaling pathway. Technol Cancer Res Treat. 19:15330338209457702020.
45	Shen Q, Jiang Q, Cong Z, Zhou Y, Huang X, Zhu L, Xu X and Qian J: Knockdown of lncRNA AL928768.3 inhibits multiple myeloma cell proliferation by inducing cell cycle arrest in G0/G1 phase. Ann Transl Med. 10:1722022.
46	Chen R, Zhang X and Wang C: LncRNA HOXB-AS1 promotes cell growth in multiple myeloma via FUT4 mRNA stability by ELAVL1. J Cell Biochem. 121:4043–4051. 2020.
47	Jia H, Liu Y, Lv S, Qiao R, Zhang X, Niu F, Shang W, Liu S, Dong J and Zhang Z: LBX2-AS1 as a novel diagnostic biomarker and therapeutic target facilitates multiple myeloma progression by enhancing mRNA stability of LBX2. Front Mol Biosci. 8:7065702021.
48	Halazonetis TD, Gorgoulis VG and Bartek J: An oncogene-induced DNA damage model for cancer development. Science. 319:1352–1355. 2008.
49	Kar S: Unraveling cell-cycle dynamics in cancer. Cell Systems. 2:8–10. 2016.
50	Basu AK: DNA damage, mutagenesis and cancer. Int J Mol Sci. 19:9702018.
51	Larsen BD, Benada J, Yung PYK, Bell RAV, Pappas G, Urban V, Ahlskog JK, Kuo TT, Janscak P, Megeney LA, et al: Cancer cells use self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress. Science. 376:476–483. 2022.
52	Hu Y, Lin J, Fang H, Fang J, Li C, Chen W, Liu S, Ondrejka S, Gong Z, Reu F, et al: Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia. 32:2250–2262. 2018.
53	Sharma S, Javadekar SM, Pandey M, Srivastava M, Kumari R and Raghavan SC: Homology and enzymatic requirements of microhomology-dependent alternative end joining. Cell Death Dis. 6:e16972015.
54	Huambachano O, Herrera F, Rancourt A and Satoh MS: Double-stranded DNA binding domain of poly(ADP-ribose) polymerase-1 and molecular insight into the regulation of its activity. J Biol Chem. 286:7149–7160. 2011.
55	Taiana E, Favasuli V, Ronchetti D, Todoerti K, Pelizzoni F, Manzoni M, Barbieri M, Fabris S, Silvestris I, Gallo Cantafio ME, et al: Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia. 34:234–244. 2020.
56	Gao D, Lv AE, Li HP, Han DH and Zhang YP: LncRNA MALAT-1 elevates HMGB1 to promote autophagy resulting in inhibition of tumor cell apoptosis in multiple myeloma. J Cell Biochem. 118:3341–3348. 2017.
57	Yang X, Huang H, Wang X, Liu H, Liu H and Lin Z: Knockdown of lncRNA SNHG16 suppresses multiple myeloma cell proliferation by sponging miR-342-3p. Cancer Cell Int. 20:382020.
58	Hamidi H and Ivaska J: Every step of the way: Integrins in cancer progression and metastasis. Nat Rev Cancer. 18:533–548. 2018.
59	Ganapathy-Kanniappan S and Geschwind JF: Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer. 12:1522013.
60	Liu N, Feng S, Li H, Chen X, Bai S and Liu Y: Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13 axis. J Cancer Res Clin Oncol. 146:367–379. 2020.
61	Tianhua Y, Dianqiu L, Xuanhe Z, Zhe Z and Dongmei G: Long non-coding RNA Sox2 overlapping transcript (SOX2OT) promotes multiple myeloma progression via microRNA-143-3p/c-MET axis. J Cell Mol Med. 24:5185–5194. 2020.
62	He X, Fan X, Zhang B, Wu L and Wu X: Expression of LINC01606 in multiple myeloma and its effect on cell invasion and migration. Am J Transl Res. 13:8777–8786. 2021.
63	Shen Y, Feng Y, Li F, Jia Y, Peng Y, Zhao W, Hu J and He A: lncRNA ST3GAL6-AS1 promotes invasion by inhibiting hnRNPA2B1-mediated ST3GAL6 expression in multiple myeloma. Int J Oncol. 58:52021.
64	Xiao Y and Yu D: Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 221:1077532021.
65	Hinshaw DC and Shevde LA: The tumor microenvironment innately modulates cancer progression. Cancer Res. 79:4557–4566. 2019.
66	Gao Y, Fang P, Li WJ, Zhang J, Wang GP, Jiang DF and Chen FP: LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma. Mol Immunol. 117:20–28. 2020.
67	Wang Z, He J, Bach DH, Huang YH, Li Z, Liu H, Lin P and Yang J: Induction of m⁶A methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance. J Exp Clin Cancer Res. 41:42022.
68	Wu L, Xia L, Chen X, Ruan M, Li L and Xia R: Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis. Leuk Res. 106:1065652021.
69	Yang N, Chen J, Zhang H, Wang X, Yao H, Peng Y and Zhang W: LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell Death Dis. 8:e29752017.
70	Wang Y, Wang H, Ruan J, Zheng W, Yang Z and Pan W: Long non-coding RNA OIP5-AS1 suppresses multiple myeloma progression by sponging miR-27a-3p to activate TSC1 expression. Cancer Cell Int. 20:1552020.
71	Wu L, Xia L, Jiang H, Hu Y, Li L, Xu L and Xia R: Long non-coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR-135b-5p to target KLF9. Mol Med Rep. 24:6492021.
72	Jiang Y, Chen J and Chen G: Long noncoding RNA IRAIN acts as tumor suppressor via miR-125b in multiple myeloma. Oncol Lett. 18:6787–6794. 2019.
73	Pu J, Huang H, Su J, Yuan J, Cong H, Wang X and Ju S: Decreased expression of long noncoding RNA XLOC_013703 promotes cell growth via NF-κB pathway in multiple myeloma. IUBMB Life. 71:1240–1251. 2019.
74	Li Z, Kumar S, Jin DY, Calin GA, Chng WJ, Siu KL, Poon MW and Chim CS: Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: Impact on prognosis and myeloma dissemination. Cancer Cell Int. 20:4032020.
75	Fechtner K, Hillengass J, Delorme S, Heiss C, Neben K, Goldschmidt H, Kauczor HU and Weber MA: Staging monoclonal plasma cell disease: Comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology. 257:195–204. 2010.
76	Shen Y, Feng Y, Chen H, Huang L, Wang F, Bai J, Yang Y, Wang J, Zhao W, Jia Y, et al: Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma. Life Sci. 196:133–142. 2018.
77	Pan Y, Chen H, Shen X, Wang X, Ju S, Lu M and Cong H: Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma. Clin Chim Acta. 480:199–205. 2018.
78	Yin Q, Shen X, Cui X and Ju S: Elevated serum lncRNA TUG1 levels are a potential diagnostic biomarker of multiple myeloma. Exp Hematol. 79:47–55.e42. 2019.
79	Xiao G, Li Y, Wang Y, Zhao B, Zou Z, Hou S, Jia X, Liu X, Yao Y, Wan J, et al: LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity. Exp Cell Res. 370:254–263. 2018.
80	Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK and Libby EN: Diagnosis and management of multiple myeloma: A review. JAMA. 327:464–477. 2022.
81	Rossi D, Fangazio M, De Paoli L, Puma A, Riccomagno P, Pinto V, Zigrossi P, Ramponi A, Monga G and Gaidano G: Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. Cancer. 116:2188–2200. 2010.
82	Kim JE, Yoo C, Lee DH, Kim SW, Lee JS and Suh C: Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol. 89:391–397. 2010.
83	Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, et al: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 78:21–33. 2003.
84	Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al: International staging system for multiple myeloma. J Clin Oncol. 23:3412–34202. 2005.
85	Yin Y, Yang W, Zhang L, Liu K and Luo Z: Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma. Hematology. 26:160–169. 2021.
86	Yu H, Peng S, Chen X, Han S and Luo J: Long non-coding RNA NEAT1 serves as a novel biomarker for treatment response and survival profiles via microRNA-125a in multiple myeloma. J Clin Lab Anal. 34:e233992020.
87	Sedlarikova L, Gromesova B, Kubaczkova V, Radova L, Filipova J, Jarkovsky J, Brozova L, Velichova R, Almasi M, Penka M, et al: Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. Eur J Haematol. 99:223–233. 2017.
88	Zhao P and Zhao X: Baseline lncRNA PCAT1 high expression and its longitude increment during induction therapy predict worse prognosis in multiple myeloma patients. J Clin Lab Anal. 35:e239242021.
89	Dong H, Jiang S, Fu Y, Luo Y, Gui R and Liu J: Upregulation of lncRNA NR_046683 serves as a prognostic biomarker and potential drug target for multiple myeloma. Front Pharmacol. 10:452019.
90	Zhou F and Guo L: Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients. Hematology. 27:596–602. 2022.
91	Xu H, Yin Q, Shen X and Ju S: Long non-coding RNA CCAT2 as a potential serum biomarker for diagnosis and prognosis of multiple myeloma. Ann Hematol. 99:2159–2171. 2020.
92	Dimopoulos MA, Barlogie B, Smith TL and Alexanian R: High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 115:931–935. 1991.
93	Shouval R, Teper O, Fein JA, Danylesko I, Shem Tov N, Yerushalmi R, Avigdor A, Vasilev E, Magen H, Nagler A, et al: LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 55:1736–1743. 2020.
94	Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, et al: Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 33:2863–2869. 2015.
95	Sedlarikova L, Bollova B, Radova L, Brozova L, Jarkovsky J, Almasi M, Penka M, Kuglík P, Sandecká V, Stork M, et al: Circulating exosomal long noncoding RNA PRINS-First findings in monoclonal gammopathies. Hematol Oncol. 36:786–791. 2018.
96	Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, et al: Treatment of multiple myeloma-related bone disease: Recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 22:e119–e130. 2021.
97	Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, et al: International Myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 34:1544–1557. 2016.
98	Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, et al: Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. Blood. 127:2955–2962. 2016.
99	Röllig C, Knop S and Bornhäuser M: Multiple myeloma. Lancet. 385:2197–2208. 2015.
100	Yang LH, Du P, Liu W, An LK, Li J, Zhu WY, Yuan S, Wang L and Zang L: LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN. Neoplasma. 68:788–797. 2021.
101	Paiva B, van Dongen JJ and Orfao A: New criteria for response assessment: Role of minimal residual disease in multiple myeloma. Blood. 125:3059–3068. 2015.
102	Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM, Siniscalchi A, et al: Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients. Blood. 117:3025–3031. 2011.
103	Ignatiadis M, Sledge GW and Jeffrey SS: Liquid biopsy enters the clinic-implementation issues and future challenges. Nat Rev Clin Oncol. 18:297–312. 2021.
104	Allegra A, Cancemi G, Mirabile G, Tonacci A, Musolino C and Gangemi S: Circulating tumour cells, cell free DNA and tumour-educated platelets as reliable prognostic and management biomarkers for the liquid biopsy in multiple myeloma. Cancers (Basel). 14:41362022.
105	Wallington-Beddoe CT and Mynott RL: Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol. 14:1512021.
106	Shen X, Zhang Y, Wu X, Guo Y, Shi W, Qi J, Cong H, Wang X, Wu X and Ju S: Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. Cancer Biomark. 18:257–263. 2017.
107	Guan R, Wang W, Fu B, Pang Y, Lou Y and Li H: Increased lncRNA HOTAIR expression promotes the chemoresistance of multiple myeloma to dexamethasone by regulating cell viability and apoptosis by mediating the JAK2/STAT3 signaling pathway. Mol Med Rep. 20:3917–3923. 2019.
108	Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, Breakefield XO and Skog JK: Exosome-based liquid biopsies in cancer: Opportunities and challenges. Ann Oncol. 32:466–477. 2021.
109	Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F and Anderson KC: Multiple myeloma. Nat Rev Dis Primers. 3:170462017.
110	Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, et al: Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients. Leukemia. 28:1122–1128. 2014.
111	Dimopoulos MA, Richardson PG, Moreau P and Anderson KC: Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 12:42–54. 2015.
112	Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 107:4907–4916. 2006.
113	Davis LN and Sherbenou DW: Emerging therapeutic strategies to overcome drug resistance in multiple myeloma. Cancers (Basel). 13:16862021.
114	Chen D, Frezza M, Schmitt S, Kanwar J and Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets. 11:239–253. 2011.
115	Pinto V, Bergantim R, Caires HR, Seca H, Guimarães JE and Vasconcelos MH: Multiple myeloma: Available therapies and causes of drug resistance. Cancers (Basel). 12:4072020.
116	Yang X, Ye H, He M, Zhou X, Sun N, Guo W, Lin X, Huang H, Lin Y, Yao R, et al: LncRNA PDIA3P interacts with c-Myc to regulate cell proliferation via induction of pentose phosphate pathway in multiple myeloma. Biochem Biophys Res Commun. 498:207–213. 2018.
117	Pan Y, Zhang Y, Liu W, Huang Y, Shen X, Jing R, Pu J, Wang X, Ju S, Cong H, et al: LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Cell Death Dis. 10:1062019.
118	Che F, Ye X, Wang Y, Ma S and Wang X: Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells. Eur J Pharmacol. 891:1737522021.
119	Chauhan D and Anderson KC: Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis. 8:337–343. 2003.
120	Wu Y and Wang H: LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. J Biochem Mol Toxicol. 32:2018 View Article : Google Scholar
121	David A, Zocchi S, Talbot A, Choisy C, Ohnona A, Lion J, Cuccuini W, Soulier J, Arnulf B, Bories JC, et al: The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling. Leukemia. 35:1710–1721. 2021.
122	Voorhees PM, Jakubowiak AJ, Kumar SK, Kanapuru B, Baines AC, Bhatnagar V, Ershler R, Theoret MR, Gormley NJ and Pazdur R: Perspectives on drug development in multiple myeloma-looking forward to 2025. Clin Cancer Res. 28:23–26. 2022.
123	Gupta A, Andresen JL, Manan RS and Langer R: Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 178:1138342021.
124	Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR and van der Meel R: The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 16:630–643. 2021.
125	K C RB, Thapa B, Valencia-Serna J, Aliabadi HM and Uludağ H: Nucleic acid combinations: A new frontier for cancer treatment. J Control Release. 256:153–169. 2017.
126	Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, et al: Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 32:1948–1957. 2018.
127	Anashkina AA, Leberfarb EY and Orlov YL: Recent trends in cancer genomics and bioinformatics tools development. Int J Mol Sci. 22:121462021.
128	Zheng H, Talukder A, Li X and Hu H: A systematic evaluation of the computational tools for lncRNA identification. Brief Bioinform. 22:bbab2852021.
129	Duan Y, Zhang W, Cheng Y, Shi M and Xia XQ: A systematic evaluation of bioinformatics tools for identification of long noncoding RNAs. RNA. 27:80–98. 2021.
130	Herman AB, Tsitsipatis D and Gorospe M: Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 82:2252–2266. 2022.
131	Volders PJ, Anckaert J, Verheggen K, Nuytens J, Martens L, Mestdagh P and Vandesompele J: LNCipedia 5: Towards a reference set of human long non-coding RNAs. Nucleic Acids Res. 47:D135–D139. 2019.
132	Ma L, Cao J, Liu L, Du Q, Li Z, Zou D, Bajic VB and Zhang Z: LncBook: A curated knowledgebase of human long non-coding RNAs. Nucleic Acids Res. 47:D128–D134. 2019.
133	Chen J, Zhang J, Gao Y, Li Y, Feng C, Song C, Ning Z, Zhou X, Zhao J, Feng M, et al: LncSEA: A platform for long non-coding RNA related sets and enrichment analysis. Nucleic Acids Res. 49:D969–D980. 2021.
134	Li Z, Liu L, Jiang S, Li Q, Feng C, Du Q, Zou D, Xiao J, Zhang Z and Ma L: LncExpDB: An expression database of human long non-coding RNAs. Nucleic Acids Res. 49:D962–D968. 2021.
135	Xie F, Liu S, Wang J, Xuan J, Zhang X, Qu L, Zheng L and Yang J: deepBase v3.0: Expression atlas and interactive analysis of ncRNAs from thousands of deep-sequencing data. Nucleic Acids Res. 49:D877–D883. 2021.
136	Li J, Han L, Roebuck P, Diao L, Liu L, Yuan Y, Weinstein JN and Liang H: TANRIC: An interactive open platform to explore the function of lncRNAs in cancer. Cancer Res. 75:3728–3737. 2015.
137	Zheng Y, Xu Q, Liu M, Hu H, Xie Y, Zuo Z and Ren J: lnCAR: A Comprehensive resource for lncRNAs from cancer arrays. Cancer Res. 79:2076–2083. 2019.
138	Bao Z, Yang Z, Huang Z, Zhou Y, Cui Q and Dong D: LncRNADisease 2.0: An updated database of long non-coding RNA-associated diseases. Nucleic Acids Res. 47:D1034–D1037. 2019.
139	Li Y, Li L, Wang Z, Pan T, Sahni N, Jin X, Wang G, Li J, Zheng X, Zhang Y, et al: LncMAP: Pan-cancer atlas of long noncoding RNA-mediated transcriptional network perturbations. Nucleic Acids Res. 46:1113–1123. 2018.
140	Gong J, Liu W, Zhang J, Miao X and Guo AY: lncRNASNP: A database of SNPs in lncRNAs and their potential functions in human and mouse. Nucleic Acids Res. 43:D181–D186. 2015.
141	Zhi H, Li X, Wang P, Gao Y, Gao B, Zhou D, Zhang Y, Guo M, Yue M, Shen W, et al: Lnc2Meth: A manually curated database of regulatory relationships between long non-coding RNAs and DNA methylation associated with human disease. Nucleic Acids Res. 46:D133–D138. 2018.
142	Todoerti K, Ronchetti D, Puccio N, Silvestris I, Favasuli V, Amodio N, Gentile M, Morabito F, Neri A and Taiana E: Dissecting the biological relevance and clinical impact of lncRNA MIAT in multiple myeloma. Cancers (Basel). 13:55182021.
143	Zhou M, Zhao H, Wang Z, Cheng L, Yang L, Shi H, Yang H and Sun J: Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. J Exp Clin Cancer Res. 34:1022015.